槲皮素联合survivin反义核苷酸对肝癌SMMC7721/ADM细胞MDR的逆转作用

目的 探讨槲皮素与survivin反义核苷酸(ASODN)联合应用对肝癌SMMC7721/ADM细胞多药耐药(MDR)的逆转作用.方法 选择肝癌敏感细胞株SMMC7721和MDR细胞株SMMC7721/阿霉素(ADM),观察其对四种不同化疗药物的耐药性及槲皮素、survivin反义核苷酸(ASODN)对SMMC7721/ADM细胞MDR的逆转效果.结果 槲皮素和ASODN联合时较两者单独应用时能显著降低四种化疗药物对SMMC7721/ADM细胞的半数抑制浓度(IC50) (P<0.05).槲皮素单独应用及联合ASODN时均能明显降低SMMC7721/ADM细胞的多药耐药基因1(MDR1)mRNA及p170和多药耐药相关蛋白基因(MRP)mRNA及p190的表达(P均<0.05). 结论 槲皮素与ASODN联合能明显逆转SMMC7721/ADM细胞对四种化疗药物的耐药性.槲皮素可能通过抑制MDR1 mRNA和MRP mRNA的表达使p170和p190的合成减少而发挥耐药逆转作用,ASODN不能通过该途径发挥作用.     

人肝癌多药耐药细胞模型的建立

目的:为研究肝癌多药耐药(MDR)机制,采用5种抗癌药物通过不同的诱导方式建立一组人肝癌MDR细胞模型。方法:利用RT-PCR、流式细胞术和四甲基偶氮唑盐(MTT)法测定MDR细胞中5种MDR基因的表达及耐药倍数。结果:SMMC7721/DOX亚系由mdr_1基因介导耐药,SMMC7721/VCR亚系由MRP基因介导耐药,SMMC7721/CBP亚系由LRP基因介导耐药,SMMC7721/VP16亚系由TopoⅡα基因介导耐药,SMMC7721/MMC亚系由GST_(P1)基因介导耐药,多重MDR亚系SMMC7721/M的耐药涉及mdr_1、MRP、URP、TopoⅡα和GST_(P1)。结论:MDR细胞模型可用于耐药研究。     

RNA干扰对胃癌耐药细胞MDR1及P-gP表达的影响

目的 寻找逆转胃癌细胞多药耐药的有效方法.方法 根据多药耐药基因1(MDR1)的基因序列,设计并体外转录合成2条siRNA,用脂质体转染将其导入人胃癌多药耐药BGC-823细胞内.应用MTT法检测转染后癌细胞生长增殖情况及对阿霉素(ADM)的敏感性,流式细胞仪检测细胞膜表面P-糖蛋白(P-gp)表达和细胞内Rh123的潴留情况.结果 转染sh-MDR1-1和sh-MDR1-2后,BGC-823细胞对ADM的IC50均降低,敏感性提高;BGC-823细胞MDR1 mRNA和P-gP表达均显著降低,细胞内Rh123稳态积累量均明显增高;上述效果均以转染sh-MDR1-1序列为著.结论 sh-MDR1-1特异性siRNA可抑制BGC-823细胞MDR1表达,此为寻找逆转胃癌细胞多药耐药有效方法奠定了基础.     

三磷酸腺苷结合盒G2调控肝癌细胞多药耐药的作用

目的探讨三磷酸腺苷结合盒(ABC)G2在肝癌耐药细胞中的表达及其在肝癌细胞耐药中的作用。方法 MTT法检测阿霉素(ADM)作用肝癌SMMC-7721细胞24 h后半数生长抑制浓度(IC50)。利用药物浓度递增细胞培养方法建立肝癌耐药细胞,在SMMC-7721细胞培养液中加入ADM,逐渐提高ADM浓度,浓度从0.001μg/ml提高至0.100μg/ml,使细胞在0.100μg/ml ADM中稳定生长,命名为SMMC-7721/ADM细胞。倒置显微镜下观察SMMC-7721/ADM及其亲代SMMC-7721细胞形态。MTT法检测ADM作用肝癌耐药细胞SMMC-7721/ADM 24 h后的IC50,计算耐药指数。流式细胞术(FCM)检测SMMC-7721/ADM及其亲代SMMC-7721细胞凋亡、周期及细胞中ABCG2蛋白表达水平。结果 ADM对SMMC-7721细胞的IC50=(1.11±0.09)μg/ml。历时3个月时间成功使SMMC-7721/ADM细胞在含0.100μg/ml ADM的细胞培养液中稳定生长,细胞命名为SMMC-7721/ADM。倒置显微镜下观察,SMMC-7721/ADM细胞体积增大,细胞形态变得更不规则。SMMC-7721/ADM与SMMC-7721细胞相比细胞凋亡率无显著差异(P0.05),细胞G0/G1期显著降低(P0.05),细胞S及G2/M期无显著差异(P0.05)。SMMC-7721/ADM与SMMC-7721细胞相比,细胞中ABCG2蛋白表达水平显著增高(P0.05)。结论 ABCG2在肝癌多药耐药细胞中异常增高,高表达的ABCG2参与了肝癌多药耐药的形成。     

多药耐药相关蛋白-3表达与肝癌耐药的相关性

目的 探讨多药耐药相关蛋白-3(MRP-3)的表达与肝癌耐药的相关性.方法 应用RT-PCR方法检测正常肝细胞L-02、肝癌细胞BEL及肝癌耐药细胞HepG2/ADM中MRP-3 mRNA的差异表达,再将MRP-3反义及正义寡核苷酸片段分别用脂质体转染进肝癌耐药细胞HepG2/ADM中,用MTT法、流式细胞仪及RT-PCR检测转染后细胞内阿霉素(ADM)的荧光强度、耐药指数及MRP-3 mRNA的表达情况.结果 肝癌耐药细胞HepG2/ADM中MRP-3 mRNA的表达明显高于正常肝细胞L-02和肝癌细胞BEL(P<0.05).MRP-3反义转染进耐药细胞后,可明显降低细胞内ADM的耐药指数,提高细胞内ADM浓度(P<0.05),细胞内MRP-3 mRNA的表达较未转染细胞下降了62.5%(P<0.05).结论 MRP-3的高表达可能是导致肝癌多药耐药的机制之一.     

辐射促进多药耐药反义寡脱氧核苷酸逆转人胰腺癌细胞耐药的实验观察

目的 探讨多药耐药基因( MDR1)反义寡核苷酸(ASON)在辐射的促进下体外逆转肿瘤细胞SW1990/FU的耐药效果.方法 采取MTT法比较MDR1的ASON直接转染与联合辐射转染的情况下SW1990/FU细胞对5-氟尿嘧啶(5-FU)的半数抑制量(IC50),再利用流式细胞仪检测两种不同的转染方法对SW1990/FU细胞的MDR1的表达产物P糖蛋白(P-gp)的调控情况.结果 MTT实验显示,联合辐射MDR1的ASON使SW1990/FU对5-FU的IC50从处理前的(129.41±8.12)nmol/L降至处理后的(3.43±0.64)nmol/L,而单纯ASON组的IC50仅降至(42.24±1.21)nmol/L,联合辐射组的逆转效果明显优于单纯ASON组 (P＜0.05).流式细胞的结果显示,辐射组SW1990/FU细胞MDR1-mRNA的P-gp 的阳性率均明显低于ASON组(P＜0.05).结论 辐射促转染的MDR1 ASON对胰腺癌细胞具有较强的耐药逆转作用.     

奥曲肽逆转肝细胞肝癌多药耐药的机制

目的 探讨生长抑素（SST）类似物奥曲肽逆转肝癌细胞多药耐药可能的机制。方法 应用MTT法分析肝癌细胞对化疗药物的敏感性；RT—PCR、流式细胞术检测肝癌细胞多药耐药基因多药耐药糖蛋白1（MDR1）、多药耐药相关蛋白2（MRP2）mRNA及其蛋白质的表达。结果 奥曲肽联合化疗药物可以显著降低化疗药物的IC50肝癌细胞有生长抑索受体2（SSTR2）、生长抑素受体3（SSTR3）、MDR1、MRP2的表达，奥曲肽可显著降低肝癌细胞表面MDR1、MRP2的表达。结论 SST可与肝癌细胞表面的SSTR结合，降低其表面MDR2、MRP2的表达，使细胞内细胞毒药物浓度增加，从而逆转肝癌细胞多药耐药。     

耐药基因反义寡脱氧核苷酸经声学微泡及超声介导转染对QGY/CDDP细胞多药耐药的影响

肿瘤细胞多药耐药(MDR)是影响肝癌治疗效果的重要因素,因此逆转MDR成为研究肝癌治疗方法的热点之一.目前没有一个有效、靶向的肿瘤MDR逆转方法[1].本研究以声学微泡+超声+mdrl或mrp反义寡脱氧核菅酸(ASODN)逆转QGY/CDDP细胞多药耐药,探讨MDR的逆转方法及其机制.     

survivin反义寡核苷酸对SMMC-7721细胞增殖和凋亡的影响

目的 观察survivin反义寡核苷酸(ASODN)对人肝癌细胞株SMMC-7721增殖和凋亡的影响.方法 人工合成survivin基因ASODN和正义ODN(SODN),并行硫代磷酸化修饰,通过脂质体途径转染SMMC-7721;分别用RT-PCR和Western blot检测survivin mRNA和蛋白表达;用MTT法检测ASODN对SMMC-7721增殖的影响;流式细胞仪检测细胞周期变化及细胞凋亡率;倒置显微镜观察细胞形态变化.结果 SMMC-7721可强表达survivin mRNA和蛋白;ASODN呈浓度依赖性抑制survivin mRNA和蛋白表达及SMMC-7721增殖,诱导细胞凋亡,使细胞阻滞于G2/M期.SODN对survivin mRNA和蛋白及SMMC-7721的增殖、细胞周期无明显抑制作用.结论 脂质体介导转染survivin ASODN可抑制细胞增殖、使细胞阻滞于G2/M期,从而促进细胞凋亡.     

Calphostin C 逆转人肾癌内源性阿霉素耐药作用的机制

目的 探讨蛋白激酶C alpha抑制剂对肾癌细胞多药耐药(MDR)逆转作用的机制.方法 应用荧光显色法、RT-PCR检测PKCα基因的表达情况及PKCα cDNA转染肾癌786-0细胞前后细胞中MDR1表达的变化;采用[14C]ADM 标记法检测PKCα激动剂Calphostin C、抑制剂PMA作用PKCα/786-0细胞系内阿霉素(ADM)浓度变化;测定PKC激动剂以及与PKC抑制剂对肾癌细胞细胞生长抑制率;分别测定ADM与PKC激动剂以及与PKC抑制剂协同作用后,786-0细胞和肾癌转染细胞系PKCα/786-0耐药性的变化.结果 肾癌转染细胞系PKCα/786-0的MDR1表达水平高于肾癌786-0细胞.Calphostin C、PMA作用后MDR1基因表达分别出现升高和降低.Calphostin C协同ADM对肾癌细胞具有较强的抑制作用,且抑制作用呈浓度依赖关系.ADM与PKC抑制剂协同作用的PKCα/786-0细胞系耐药性明显降低.结论 PKCαcDNA的转染可以提高786-0细胞的耐药性,而PKCα的选择性激动剂和选择性抑制剂则分别可以增加和逆转肾癌细胞对ADM的耐药性,其途径可能是通过促使肾癌细胞内源性ADM耐药发生变化进而影响细胞内化疗药物的浓度来实现的.     

Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells

BACKGROUND AND AIMS: Insulin-like growth factors (IGFs) are closely related to hepatocellular carcinoma growth. The study aim was to investigate the effects of IGF-IR and IGF-IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells. METHODS: 7721-IGF-IR-AS cells (human hepatoma SMMC-7721 cells transfected with IGF-IR antisense gene in our previous study) were transfected with a plasmid vector expressing IGF-IIR cDNA in the antisense orientation by DOTAP liposome.7721-IGF-R-AS cells were obtained by selection with G418 and hygromycin. Morphological changes of the cells were observed with optic and electron microscopes. In vitro growth of the 7721-IGF-R-AS cells was observed with a soft agar test, MTT test and with naked mice inoculation test in vivo. RESULTS: The following changes were found in the SMMC-7721 cells after being transfected with the IGF-IR and IGF-IIR antisense genes: (i) the degree of malignancy of the tumor cells as revealed by cell morphology was ameliorated; (ii) the growth capability of the tumor cells in soft agar and their tumorigenicity in naked mice were significantly depressed. However, in the control groups, the SMMC-7721 cells transfected both with IGF-IR and IGF-IIR sense cDNA and SMMC-7721 cells transfected without any external genes, had no such changes. However, the cell growth curves had no significant differences among these three groups. CONCLUSION: IGF-IR and IGF-IIR antisense genes could significantly restrain the malignant behavior of human hepatoma cells and might be useful in investigating a potential route for hepatocellular carcinoma gene therapy.     

JNK1,JNK2,and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells

BACKGROUND:Multidrug resistance(MDR)is extremely common in hepatocellular carcinoma(HCC)and is a major problem in cancer eradication by limiting the efficacy of chemotherapy.Modulation of c-Jun NH2-terminal kinase(JNK)activation could be a new method to reverse MDR.However,the relationship between JNK activity and MDR in HCC cells is unknown.This study aimed to explore the relationship between MDR and JNK in HCC cell lines with different degrees of MDR.METHODS:A MDR human HCC cell line,SMMC-7721/ ADM,was developed by exposing parental cells to gradually increasing concentrations of adriamycin.The MTT assay was used to determine drug sensitivity.Flow cytometry was used to analyze the cell cycle distribution and to measure the expression levels of P-glycoprotein(P-gp)and MDR-related protein(MRP)-1 in these cells.JNK1,JNK2 and JNK3 mRNA expression levels were quantified by real-time PCR.Expression and phosphorylation of JNK1,JNK2,and JNK3 were analyzed by Western blotting.RESULTS:The MDR of SMMC-7721/ADM cells resistant to 0.05 mg/L adriamycin was mainly attributed to the overexpression of P-gp but not MRP1.In addition,these cells had a significant increase in percentage in the S phase,accompanied by a decrease in percentage in the G0/G1 phase,which is likely associated with a reduced ability for cell proliferation and MDR generation.We found that JNK1,JNK2,and JNK3 activities were negatively correlated with the degree of MDR in HCC cells.CONCLUSION:This study suggests that JNK1,JNK2,and JNK3 activities are negatively correlated with the degree of MDR in HCC cells.     

Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug—resistant cell line SMMC—7721／R

AIM：To investigate the correlation between subcellular daunorubicin distribution and the multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.METHODS:The multidrug resistant cell line SMMC-7721/R,a human hepatocellular carcinoma cell line,was established.Antisenes oligonucleotides(AS-ODN)were used to obtain different multidrug resistance phenotypes by inhibiting the expression of mdr1 gene and/or multidrug resistance-related protein gene(mrp)using Lipofectamine as delivery agent.Expression of mdr1 and mrp genes was evaluated by RT-PCRand Western blotting.Intracellular daunorubicn(DNR)concentration was measured by flow cytometry.Subcellular DNR distribution was analyzed by confocal laser scanning microscopy.Adriamycin(ADM)and DNR sensitivity was examined by MTTmethod.RESULTS:Low level expression of mdr1 and mrpmRNAs and no expression of P-Glycoprotein(P-gp)and multidrug resistance-related protein(P190)were detected in parental sensitive cells SMMC-7721/S,but over-expression of these two genes was observed in drug-resistant cell SMMC-7721/R,The expression of mdr1 and mrp genes in SMMC-7721/Rcells was down-regulated to the level in the SMMC-7721/Scells by AS-ODN.Intracellular DNAconcentration in SMMC-7721/Scells was 10times higher than that in SMMC-7721/Rcells.In SMMC7721/Scells intracellular DNA distributed evenly in the nucleus and cytoplasm.while in SMMC-7721/Rcells DNR distributed in a punctate pattern in the cytoplasm and was reduced in the nucleus.DNR concentration in SMMC-7721/Rcells co-transfected with AS-ODNs targeting to mdr1and rpmRNAs recovered to 25percent of that in SMMC7721/Scells.Intracellular DNA distribution pattern in drug-resistant cells treated by AS-ODN was similar to drug-sensitive cell.and the cells resistance index(RI)to DNA and AMD decreased at most from 88.0and 116.0to4.0and 2.3,repectively.Co-Transfection of two AS-ODNs showed a stronger synergistic effect than separate transfection.CONCLUSIONS:P-gp and P190are two members mediatingMDR in cellline SMMC7721/R,Intracellular drug concentration increase and subcellular distribution change are two important factos in multidrug resistance(MDR)formation.The second facto,drugs transport by P-gp andP190from cell nucleus to organell in cytoplasm,may play a more important role.     

Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells

AIM： To study the expression and phosphorylation of extracellular signal-regulated kinase （ERK） i and ERK2 in multidrug resistant （MDR） hepatocellular carcinoma （HCC） cells.
METHODS： MDR HCC cell lines, HepG2/adriamycin （ADM） and SMMC7721/ADM, were developed by exposing parental cells to stepwise increasing concentrations of ADM. MTT assay was used to determine drug sensitivity. Flow cytometry was employed to analyze cell cycle distribution and measure cell P-glycoprotein （P-gp） and multidrug resistant protein 1 （MRP1） expression levels. ERK1 and ERK2 mRNA expression lev-ls were measured by quantitative real-time PCR （QRTPCR）. Expression and phosphorylation of ERK1 and ERK2 were analyzed by Western blot.
RESULTS： MTT assay showed that HepG2/ADM andSMMC7721/ADM were resistant not only to ADM, but also to multiple anticancer drugs. The P-gp expression was over 10-fold higher in HepG2/ADM cells than in HepG2 cells （8.92% ±0.22% vs 0.88% ± 0.05%, P 〈 0.001） and over 4-fold higher in SMMC7721/ADM cells than in SMMC7721 cells （7.37% ± 0.26% vs 1.74% ± 0.25%, P 〈 0.001）. However, the MRP1 expression was not significantly higher in HepG2/ADM and SMMC7721/ADM cells than in parental cells. In addition, the percentage of MDR HepG2/ADM and SMMC7721/ADM cells was significantly decreased in the G0/G1 phase and increased in the the S phase or G2/M phase. QRT-PCR analysis demonstrated that the ERK1 and ERK2 mRNA expression increased apparently in HepG2/ADM cells and decreased significantly in SMMC7721/ADM cells. Compared with the expression of parental cells, ERK1 and ERK2 protein expressions were markedly decreased in SMMC7721/ADM cells. However, ERK2 protein expression was markedly increased while ERK1 protein expression had no significant change in HepG2/ADM cells. Phosphorylation of ERK1 and ERK2 was markedly decreased in both HepG2/ADM and SMMC7721/ADM MDR cells.
CONCLUSION： ERK1 and ERK2 activities are downregulated in P-gp-mediated MDR HCC cells. ERK1 or ERK2 might be a potential drug target for circumventing MDR HCC cells,     

Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells

Introduction The overexpression of the multidrug resistance gene 1 (mdr1), a product of multidrug resistance multidrug resistance, is a major obstacle in cancer chemotherapy. Being a major P-glycoproteincancer chemotherapy. Being a major P-glycoprotein (P-gp), 17 kDa transmembrane protein acts as an energy-dependent drug efflux pump and keeps the concentration and efficacy intracellular anticancer drugs low.[1-4] Hepatocellular carcinoma (HCC) represents more than 5% of all cancers in the w…     

RNA干扰p21对肝癌细胞SMMC-7721增殖的影响

目的:探讨RNA干扰技术沉默p21基因对肝癌细胞SMMC-7721增殖及恶性表型变化的影响.方法:通过慢病毒载体将p21小干扰RNA片段稳定转染入SMMC-7721细胞,通过RT-PCR,Western blot分别检MJp21 Mrna和蛋白表达变化,流式细胞仪检测7721-p2l RNAi组(感染p21 siRNA...     

血管内皮细胞生长因子反义核糖核酸对肝癌细胞生长的抑制作用

目的 探讨血管内皮细胞生长因子(VEGF)反义RNA转染人肝癌细胞后对细胞体内外生物学性状的影响。方法 将含正义、反义VEGFcDNA序列的质粒PCMV—VEGF、PCMV—FGEV及空载体质粒pcDNA3.1,在脂质体介导下导入SMMC—7721肝癌细胞,分别称为正义、反义及对照组,并通过G418筛选获得阳性克隆。细胞原位杂交和免疫组织化学方法检测转染后VEGF在肝癌细胞内的表达情况;MTT法和FCM检测转染后细胞在体外的增殖和凋亡情况;并制备裸鼠动物模型,观察转染后细胞的体内生长情况。结果 转染PCMV—FGEV后肝癌细胞内VEGF的转录及其蛋白的表达水平显著下降,但转染后体外细胞的增殖与凋亡情况均无明显变化。转染PCMV—FGEV后细胞在裸鼠体内的生长缓慢,反义组成瘤时间为(25.0±1.8)d,明显长于正义组(15.7±2.5)d和对照组(18.5±2.1)d,F=19.455,P<0.01;而平均瘤重以反义组最轻,为(0.96±0.28)g,F=21.501,P<0.01;同时反义组裸鼠肿瘤细胞发生明显的凋亡。结论 VEGF反义RNA转染人肝癌细胞可抑制肿瘤细胞VEGF的表达,在体外对细胞增殖和凋亡无影响,而体内可显著诱导细胞凋亡并抑制肿瘤生长。     

Expression of angiostatin cDNA in human hepatocellular carcinoma cell line SMMC-7721 and its effect on implanted carcinoma in nude mice

AIM: To transfect murine angiostatin cDNA into human hepatocellular carcinoma cell line SMMC-7721 and to investigate its effects on implanted carcinoma in nude mice. METHODS: A eukaryotic expression vector of pcDNA3.1-mAST containing murine angiostatin was constructed. Then pcDNA3.1-mAST plasmid was transfected into cell line SMMC-7721 by Lipofectamine. The resistant clone was screened by G418 filtration and identified by RT-PCR and Western blotting. Nude mice were divided into three groups of 10 each. Mice in blank control group were only injected with SMMC-7721 cells. Mice in vector control group were injected with SMMC-7721 cells transfected with pcDNA3.1 (+) vector, whereas mice in angiostatin group were injected with SMMC-7721 cells transfected with pcDNA3.1-mAST plasmid. Volume, mass and microvessel density (MVD) of the tumors in different groups were measured and compared. RESULTS: Murine angiostatin cDNA was successfully cloned into the eukaryotic expression vector pcDNA3.1 (+). pcDNA3.1-mAST was successfully transfected into SMMC-7721 cell line and showed stable expression in this cell line. No significant difference was observed in the growth speed of SMMC-7721 cells between groups transfected with and without angiostatin cDNA. Tumor volume, mass and MVD in the angiostatin group were significantly lower than those in the blank control group and vector control group (P<0.01). The inhibitory rate of tumor reached 78.6%. Mass and MVD of the tumors only accounted for 34.6% and 48.9% respectively of those in the blank control group. CONCLUSION: Angiostatin cDNA could be stably expressed in human hepatocellular carcinoma cell line SMMC-7721 without obvious inhibitory effects on the growth of SMMC-7721 cells. When implanted into nude mice, SMMC-7721 cells transfected with angiostatin cDNA show a decreased tumorigenic capability. It suggests that angiostatin can inhibit tumor growth through its inhibition on angiogenesis in tumors.     

Inhibitory effect of antisense vascular endothelial growth factor RNA on the profile of hepatocellular carcinoma cell line in vitro and in vivo

AIM:To evaluate the effect of antisense vascularendothelial growth factor(VEGF)RNA(PCMV-FGEV)transfection on the profile of hepatocellular carcinoma(HCC)SMMC-7721 cells in vitro and in vivo.METHODS:SMMC-7721 cells were transfectedwith PCMV-FGEV antisense,PCMV-VEGF sense andempty vector plasmid encapsulated by lipofectamineas antisense group,sense group and control grouprespectively.The positive cell clones were selectedwith G418.The stable transfection and expressionof VEGF in the cells were determined by RT-PCR andimmunohistochemistry.Cell proliferation was observedby MTT assay.FACS analysis was used to determine theeffect of PCMV-FGEV transfection on cell apoptosis.Thegrowth of transfected cells in Wvo was also observed innude mice.RESULTS:VEGF expression was reduced in SMMC-7721transfected with PCMV-FGEV,which was confirmed byRT-PCR and immunohistochemistry.No effect of PCMV-FGEV transfection was found on cell proliferation andcell apoptosis of SMMC-7721 in vitro.The growth of cellstransfected with PCMV-FGEV was slow in nude miceand accompanied with obvious apoptosis.The latenttime of tumors in the antisense group was 25.0±1.8d,which was longer than that in sense and controlgroups(F=19.455,P<0.01).The average tumor weightin antisense group(0.96 g±0.28 g)was the smallestamong the three groups(F=21.501,P<0.01).CONCLUSION:The expression of VEGF can be inhibitedby antisense PCMV-FGEV.Antisense PCMV-FGEV has no effect on cell proliferation and apoptosis of SMMC-7721in vitro but can inhibit tumor growth and induce cellapoptosis in vivo.     

人胰岛素样生长因子Ⅱ反义RNA对肝癌细胞恶性表型的抑制作用

研究人胰岛素样生长因子Ⅱ（ＩＧＦ－Ⅱ）反义ＲＮＡ对肝癌细胞株ＳＭＭＣ－７７２１的抑制效应。方法人ＩＧＦ－ⅡｃＤＮＡ０．１ｋｂ反向插人真核细胞表达载体ｐｃＮＡ３,获得ＩＧＦ－Ⅱ反义ＲＮＡ表达载体ｐＩＧＦ－ⅡＡＳ,将其导人人肝癌细胞株ＳＭＭＣ-７７２１,观察软琼脂培养集落形成的能力。流式细胞仪（ＦＣＭ）测定ｐＩＧＦ－ⅡＡｓ表达ＩＧＦ－Ⅱ反义ＲＮＡ对ＳＭＭＣ-７７２１细胞生长的影响。结果转导人ｐＩＧＦ－ⅡＡｓ的ＳＭＭＣ－７７２１细胞,不能在软琼脂上形成集落,ＦＣＭＭ实导人ＰＩＧＦ－ⅡＡｓ细胞Ｓ期增多,而对照组ＳＭＭＣ－７７２１细胞和带ＤＣＤＮＡ３空载体的ＳＭＭＣ－７７２１细胞则无明显变化．结论ｐＩＧＦ-ⅡＡＳ＆义ＲＮＡ体外可抑制肝癌细胞株ＳＭＭＣ－７７２１的致瘤性。